Darwin Global Management, Ltd.
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Darwin Global Management, Ltd. reported 5 stock positions worth $3.8 billion. Its top holding was Revolution Medicines (RVMD) at 54.5% of the portfolio, followed by Insmed (INSM, 17.9%) and Belite Bio Inc. - ADR (BLTE, 12.1%). Compared with Q1 2026, it sold out of 1, added to 3 and reduced 2. The biggest buy was Revolution Medicines (RVMD, shares +381%) and the biggest sale Insmed (INSM, shares −62%).
- Most Recent 13F
- Q2 2026
- Location
- ST. HELIER, Y9
- CIK
- 0001839209
- Portfolio Value
- $3.8B (Q2 2026)
- SEC Filing
- 0001892688-26-000126 ↗ filed Aug 14, 2026
Holdings Value
Holdings 5 stocks · $3.8B
| RVMD Revolution Medicines Inc. | 54.45% | 10,629,822 | $2.0B | Add +380.8% |
| INSM Insmed Inc. | 17.91% | 6,431,163 | $673.6M | Reduce -61.7% |
| BLTE Belite Bio Inc. - ADR | 12.14% | 3,077,219 | $456.6M | Add +0.7% |
| ABVX Abivax SA-ADR | 9.26% | 3,621,583 | $348.2M | Add +4.4% |
| ROIV Roivant Sciences Ltd. | 6.23% | 6,747,300 | $234.3M | Reduce -0.7% |
Portfolio Sells Q1 2026 → Q2 2026
Portfolio Buys Q1 2026 → Q2 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $3.8B | RVMD, INSM, BLTE, ABVX, ROIV |
| Q1 2026 | 6 | $3.8B | INSM, BLTE, ABVX, RVMD, ROIV |
| Q4 2025 | 6 | $4.9B | INSM, BLTE, ABVX, CDTX, WVE |
| Q3 2025 | 5 | $3.6B | INSM, UTHR, ABVX, CDTX, QURE |
| Q2 2025 | 5 | $2.4B | INSM, VRNA, CDTX, MRUS, ALLO |
| Q1 2025 | 3 | $1.5B | INSM, VRNA, ALLO |
| Q4 2024 | 6 | $1.1B | INSM, JAZZ, VRNA, GERN, KROS |
| Q3 2024 | 5 | $1.2B | INSM, PCVX, GERN, KROS, SMMT |
| Q2 2024 | 9 | $859.5M | CYTK, INSM, PCVX, GERN, KROS |
| Q1 2024 | 12 | $751.2M | PCVX, NUVL, KROS, BHVN, ALPN |